Your shopping cart is empty

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > Bayer’s Metastatic Colorectal Cancer Drug Submitted for Approval in U.S., EU

Washington Drug Letter

June 4, 2012 | Vol. 44 No. 23

Bayer’s Metastatic Colorectal Cancer Drug Submitted for Approval in U.S., EU

Bayer HealthCare has submitted applications to the FDA and European Medicines Agency for its metastatic colorectal cancer treatment regorafenib.

This article is viewable by subscribers only. To view this article, please select an option below.

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.